{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:06:46Z","timestamp":1788934006378,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020898","name":"Universidade Federal De Ci\u00eancias Da Sa\u00fade De Porto Alegre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020898","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Ototoxicity caused by chemotherapy is a growing problem. Literature highlights the effects of platinum compounds. However, other chemotherapy drugs also have demonstrated audiological changes. The objective of this study was to compare pre- and post-treatment distortion product otoacoustic emissions (DPOAEs) in adult patients undergoing different chemotherapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cohort study comprising 174 individuals receiving chemotherapy (CT) between April 2022 and December 2023. DPOAE were evaluated in all patients at 2\u00a0kHz, 4\u00a0kHz, 6\u00a0kHz, 8\u00a0kHz, 10\u00a0kHz, and 12\u00a0kHz, before initiating chemotherapy and after completing the treatment. For differential analysis, the protocols were grouped into CT with platinum-based agents and other protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A reduction in response in at least one frequency of the DPOAE test was observed in 79% of the patients. 81% of those who received CT without platinum derivatives exhibited alterations in post-treatment examinations, whereas in the group with platinum-based compounds, alterations were observed in 79% of the subjects. Different percentages of response deterioration were observed across frequencies: 27.6% at 2\u00a0kHz, 24.6% at 4\u00a0kHz, 41.2% at 6\u00a0kHz, 58.8% at 8\u00a0kHz, 57.4% at 10\u00a0kHz, and 72.4% at 12\u00a0kHz. The ototoxic effect of chemotherapy protocols, with and without platinum, was more pronounced at higher frequencies, with no statistically significant difference between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Chemotherapy has shown signs of ototoxicity through changes in DPOAEs in the sample studied. The ototoxic effects were similar between drug protocols with and without platinum, highlighting the need for audiological monitoring in all chemotherapy patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-026-04944-3","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:30:11Z","timestamp":1788931811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ototoxicity beyond platinum-based derivatives"],"prefix":"10.1007","volume":"96","author":[{"given":"Cec\u00edlia Vieira","family":"Peruch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Salgado","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Beatris","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Oliveira Goulart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalise Costa","family":"Batista Berbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Dallegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"4944_CR1","doi-asserted-by":"crossref","unstructured":"Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM (2022) Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer Epidemiol [Internet]. Aug 1 [cited 2025 Jan 27];79. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35724557\/","DOI":"10.1016\/j.canep.2022.102203"},{"key":"4944_CR2","doi-asserted-by":"crossref","unstructured":"Kessler L, Koo C, Richter CP, Tan X Hearing loss during chemotherapy: prevalence, mechanisms, and protection. Am J Cancer Res [Internet]. 2024 [cited 2025 Jan 15];14(9):4597. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11477841\/","DOI":"10.62347\/OKGQ4382"},{"key":"4944_CR3","doi-asserted-by":"publisher","unstructured":"Saito T, Zhang ZJ, Tokuriki M, Shibamori Y, Yamamoto T, Noda I et al (2001) Doxorubicin Ototoxicity is Induced in Mice by Combination Treatment with Cyclosporin A. Acta Otolaryngol [Internet]. [cited 2025 Jan 15];121(7):787\u201393. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/00016480152602212","DOI":"10.1080\/00016480152602212"},{"key":"4944_CR4","doi-asserted-by":"crossref","unstructured":"Xuan L, Sun B, Meng X, Liu C, Cong Y, Wu S Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases. Cancer Biol Ther [Internet]. 2020 Nov 1 [cited 2025 Jan 12];21(11):990\u20133. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33121320\/","DOI":"10.1080\/15384047.2020.1831370"},{"issue":"7","key":"4944_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/s0959-8049(97)10137-x","volume":"34","author":"C Tibaldi","year":"1998","unstructured":"Tibaldi C, Pazzagli I, Berrettini S, De Vito A (1998) A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine [1]. Eur J Cancer 34(7):1133https:\/\/doi.org\/10.1016\/s0959-8049(97)10137-x https:\/\/doi.org\/10.1016\/s0959-8049(97)10137-x","journal-title":"Eur J Cancer"},{"key":"4944_CR6","doi-asserted-by":"publisher","unstructured":"Cheung SW, Henderson-Sabes J, Mastick J, Abrams G, Snowberg K, Alfaro E et al (2023) Cancer Survivors and Neurotoxic Chemotherapy: Hearing loss and tinnitus BMJ supportive & palliative care, 13(3), 345\u2013353. https:\/\/doi.org\/10.1136\/spcare-2022-003684 https:\/\/doi.org\/10.1136\/spcare-2022-003684H","DOI":"10.1136\/spcare-2022-003684H"},{"key":"4944_CR7","doi-asserted-by":"publisher","unstructured":"G\u00fcven\u00e7 MG, Dizdar D, Dizdar SK, Okutur SK, Demir G Sudden hearing loss due to oxaliplatin use in a patient with colon cancer. J Chemother [Internet]. 2016 Jul 3 [cited 2025 Jan 15];28(4):341\u20132. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1179\/1973947815Y.0000000023","DOI":"10.1179\/1973947815Y.0000000023"},{"issue":"6","key":"4944_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/014556131008900607","volume":"89","author":"NK Malhotra","year":"2010","unstructured":"Malhotra NK, Aslam R, Lipman SP, Bilski VJ (2010) Acute ototoxicity from a single infusion of oxaliplatin. Ear. Nose Throat J 89(6):258\u2013261","journal-title":"Nose Throat J"},{"key":"4944_CR9","doi-asserted-by":"crossref","unstructured":"Jenkins V, Beveridge H, Low R, Mitra S Atypical hearing loss in women with breast cancer receiving adjuvant treatment. Breast [Internet]. 2006 [cited 2025 Jan 29];15(3):447\u201350. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16135407\/","DOI":"10.1016\/j.breast.2005.06.005"},{"key":"4944_CR10","doi-asserted-by":"crossref","unstructured":"Shetty S, Bhandary SK, Bhat V, Aroor R, Shetty J, Dattatreya T Role of Otoacoustic Emission in Early Detection of Cisplatin Induced Ototoxicity. Indian J Otolaryngol Head Neck Surg [Internet]. 2022 Aug 1 [cited 2022 Oct 23];74(Suppl 1):164\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36032922","DOI":"10.1007\/s12070-020-01933-7"},{"key":"4944_CR11","doi-asserted-by":"crossref","unstructured":"Wang Y, Li X, Ren F, Liu S, Ma W, Zhang Y et al (2022) High-Frequency Cochlear Amplifier Dysfunction: A Dominating Contribution to the Cognitive-Ear Link. Front Aging Neurosci [Internet]. Jan 6 [cited 2025 Feb 2];13:767570. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8770931\/","DOI":"10.3389\/fnagi.2021.767570"},{"key":"4944_CR12","unstructured":"Conselho Federal de Fonoaudiologia. RESOLU\u00c7\u00c3O CFFa no 553 [Internet]. Oct 2 (2019) Available from: https:\/\/www.fonoaudiologia.org.br\/resolucoes\/resolucoes_html\/CFFa_N_553_19.htm"},{"key":"4944_CR13","doi-asserted-by":"crossref","unstructured":"Kim DO, Paparello J, Jung MD, Smurzynski J, Sun X (1996) Distortion product otoacoustic emission test of sensorineural hearing loss: performance regarding sensitivity, specificity and receiver operating characteristics. Acta Otolaryngol [Internet]. [cited 2025 Jan 26];116(1):3\u201311. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8820343\/","DOI":"10.3109\/00016489609137705"},{"key":"4944_CR14","doi-asserted-by":"publisher","unstructured":"Konrad-Martin D, Helt WJ, Reavis KM, Gordon JS, Coleman LL, Bratt GW et al Ototoxicity: Early Detection and Monitoring. ASHA Lead [Internet]. 2005 [cited 2025 Jan 24];10(7). Available from: https:\/\/leader.pubs.asha.org\/doi\/https:\/\/doi.org\/10.1044\/leader.FTR1.10072005.1","DOI":"10.1044\/leader.FTR1.10072005.1"},{"key":"4944_CR15","doi-asserted-by":"crossref","unstructured":"Beattie RC, Kenworthy OT, Luna CA (2003) Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol [Internet]. [cited 2022 Oct 31];42(6):348\u201354. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14570243\/","DOI":"10.3109\/14992020309101328"},{"issue":"1","key":"4944_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11764-022-01315-8","volume":"17","author":"JR DeBacker","year":"2023","unstructured":"DeBacker JR, McMillan GP, Martchenke N, Lacey CM, Stuehm HR, Hungerford ME et al (2023) Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review. J Cancer Surviv 17(1):82\u2013100https:\/\/doi.org\/10.1007\/s11764-022-01315-8 https:\/\/doi.org\/10.1007\/s11764-022-01315-8","journal-title":"J Cancer Surviv"},{"issue":"1","key":"4944_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1682\/JRRD.2013.04.0092","volume":"51","author":"D Konrad-Martin","year":"2014","unstructured":"Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M (2014) Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev 51(1):81\u2013100https:\/\/doi.org\/10.1682\/JRRD.2013.04.0092 https:\/\/doi.org\/10.1682\/JRRD.2013.04.0092","journal-title":"J Rehabil Res Dev"},{"key":"4944_CR18","doi-asserted-by":"crossref","unstructured":"Biro K, Noszek L, Prekopp P, Nagyiv\u00e1nyi K, G\u00e9czi L, Gaudi I et al (2006) Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology [Internet]. Jul [cited 2022 Oct 13];70(3):177\u201384. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16757924\/","DOI":"10.1159\/000093776"},{"key":"4944_CR19","doi-asserted-by":"crossref","unstructured":"Hunter LL, Monson BB, Moore DR, Dhar S, Wright BA, Munro KJ et al Extended high frequency hearing and speech perception implications in adults and children. Hear Res [Internet]. 2020 Nov 1 [cited 2025 Feb 2];397:107922. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7431381\/","DOI":"10.1016\/j.heares.2020.107922"},{"key":"4944_CR20","doi-asserted-by":"crossref","unstructured":"Mishra SK, Saxena U, Rodrigo H (2022) Extended High-frequency Hearing Impairment Despite a Normal Audiogram: Relation to Early Aging, Speech-in-noise Perception, Cochlear Function, and Routine Earphone Use. Ear Hear [Internet]. May 12 [cited 2025 Feb 2];43(3):822\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34700326\/","DOI":"10.1097\/AUD.0000000000001140"},{"key":"4944_CR21","doi-asserted-by":"crossref","unstructured":"Yeend I, Beach EF, Sharma M Working Memory and Extended High-Frequency Hearing in Adults: Diagnostic Predictors of Speech-in-Noise Perception. Ear Hear [Internet]. 2019 May 1 [cited 2025 Feb 2];40(3):458\u201367. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30052557\/","DOI":"10.1097\/AUD.0000000000000640"},{"key":"4944_CR22","doi-asserted-by":"crossref","unstructured":"Arnold DJ, Lonsbury-Martin BL, Martin GK High-Frequency Hearing Influences Lower-Frequency Distortion-Product Otoacoustic Emissions. Arch Otolaryngol Neck Surg [Internet]. 1999 Feb 1 [cited 2025 Feb 2];125(2):215\u201322. Available from: https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/509048","DOI":"10.1001\/archotol.125.2.215"},{"key":"4944_CR23","doi-asserted-by":"crossref","unstructured":"Y\u00fcce S, \u015eeker MM, Ko\u00e7 S, Uysal I\u00d6, Ka\u00e7an T, Do\u01e7an M et al Oxaliplatin and ototoxicity: is it really safe for hearing? Turkish J Med Sci [Internet]. 2014 Jan 1 [cited 2025 Jan 15];44(4):586\u20139. Available from: https:\/\/journals.tubitak.gov.tr\/medical\/vol44\/iss4\/9","DOI":"10.3906\/sag-1304-76"},{"issue":"1","key":"4944_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12029-013-9489-3","volume":"45","author":"FZ Hijri","year":"2014","unstructured":"Hijri FZ, Arifi S, Ouattassi N, Mellas N, El Mesbahi O (2014) Oxaliplatin-induced ototoxicity in adjuvant setting for colorectal cancer: Unusual side effect. J Gastrointest Cancer 45(1):106\u2013108https:\/\/doi.org\/10.1007\/s12029-013-9489-3 https:\/\/doi.org\/10.1007\/s12029-013-9489-3","journal-title":"J Gastrointest Cancer"},{"key":"4944_CR25","unstructured":"Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW (2013) Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP [Internet]. [cited 2025 Jan 15];14(6):676\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24216561\/"},{"key":"4944_CR26","doi-asserted-by":"crossref","unstructured":"Nirban RK, Kapoor A, Narayan S, Maharia S, Singhal MK, Kumar HS Ototoxicity following Vinblastine chemotherapy in a patient of Hodgkin\u2032s Lymphoma. Indian J Otol [Internet]. 2015 Jul 1 [cited 2025 Jan 26];21(3):229\u201330. Available from: https:\/\/journals.lww.com\/ijoo\/fulltext\/2015\/21030\/ototoxicity_following_vinblastine_chemotherapy_in.18.aspx","DOI":"10.4103\/0971-7749.161071"},{"issue":"3","key":"4944_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1179\/joc.2003.15.3.290","volume":"15","author":"MT Kalcioglu","year":"2003","unstructured":"Kalcioglu MT, Kuku I, Kaya E, Oncel S, Aydogdu I (2003) Bilateral Hearing Loss During Vincristine Therapy: A Case Report. J Chemother 15(3):290\u2013292 https:\/\/doi.org\/10.1179\/joc.2003.15.3.290 https:\/\/doi.org\/10.1179\/joc.2003.15.3.290","journal-title":"J Chemother"},{"issue":"4","key":"4944_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1345\/aph.18288","volume":"33","author":"PE Moss","year":"1999","unstructured":"Moss PE, Hickman S, Harrison BR (1999) Ototoxicity associated with vinblastine. Ann Pharmacother 33(4):423\u2013425https:\/\/doi.org\/10.1345\/aph.18288 https:\/\/doi.org\/10.1345\/aph.18288","journal-title":"Ann Pharmacother"},{"key":"4944_CR29","doi-asserted-by":"publisher","unstructured":"Barbieri MA, Cicala G, Cutroneo PM, Mocciaro E, Sottosanti L, Freni F et al (2019) Ototoxic adverse drug reactions: A disproportionality analysis using the Italian spontaneous reporting database. Frontiers in pharmacology, 10, 1161. https:\/\/doi.org\/10.3389\/fphar.2019.01161 https:\/\/doi.org\/10.3389\/fphar.2019.01161","DOI":"10.3389\/fphar.2019.01161"},{"key":"4944_CR30","doi-asserted-by":"publisher","unstructured":"Campbell KCM (2011) Detection of Ototoxicity. Proc Widex Pediatr Audiol [Internet]. [cited 2022 Nov 2];32:196\u2013202. Available from: https:\/\/doi.org\/10.1055\/s-0031-1277242","DOI":"10.1055\/s-0031-1277242"},{"issue":"1","key":"4944_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1121\/10.0011739","volume":"152","author":"CG Le Prell","year":"2022","unstructured":"Le Prell CG, Brewer CC, Campbell KCM (2022) The audiogram: Detection of pure-tone stimuli in ototoxicity monitoring and assessments of investigational medicines for the inner ear. J Acoust Soc Am 152(1):470\u2013490 https:\/\/doi.org\/10.1121\/10.0011739","journal-title":"J Acoust Soc Am"},{"issue":"11","key":"4944_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/cncr.29779","volume":"122","author":"W Landier","year":"2016","unstructured":"Landier W (2016) Ototoxicity and cancer therapy. Cancer 122(11):1647\u20131658https:\/\/doi.org\/10.1002\/cncr.29779 https:\/\/doi.org\/10.1002\/cncr.29779","journal-title":"Cancer"},{"issue":"1","key":"4944_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ol.2012.997","volume":"5","author":"A Nitz","year":"2012","unstructured":"Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T et al (2012) Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 5(1):311\u2013315https:\/\/doi.org\/10.3892\/ol.2012.997 https:\/\/doi.org\/10.3892\/ol.2012.997","journal-title":"Oncol Lett"},{"key":"4944_CR34","doi-asserted-by":"crossref","unstructured":"Budai B, Prekopp P, Noszek L, Kov\u00e1cs ER, Sz\u0151nyi M, Erd\u00e9lyi DJ et al GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. J Mol Med (Berl) [Internet]. 2020 Jul 1 [cited 2025 Jan 14];98(7):963\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32435918\/","DOI":"10.1007\/s00109-020-01921-y"},{"issue":"6","key":"4944_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bjorl.2015.11.021","volume":"82","author":"PHP Liberman","year":"2016","unstructured":"Liberman PHP, Goffi-Gomez MVS, Schultz C, Novaes PE, Lopes LF (2016) Audiological profile of patients treated for childhood cancer. Braz J Otorhinolaryngol 82(6):623\u2013629 https:\/\/doi.org\/10.1016\/j.bjorl.2015.11.021 https:\/\/doi.org\/10.1016\/j.bjorl.2015.11.021","journal-title":"Braz J Otorhinolaryngol"},{"key":"4944_CR36","unstructured":"Minist\u00e9rio da Sa\u00fade (2023) Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva Minist\u00e9rio da Sa\u00fade Instituto Nacional de C\u00e2ncer https:\/\/www.inca.gov.br\/publicacoes\/livros\/estimativa-2023-incidencia-de-cancer-no-brasil"},{"key":"4944_CR37","doi-asserted-by":"crossref","unstructured":"Laure G, Borg E Ototoxicity of Cisplatin in Gynaecological Cancer Patients. Scand Audiol [Internet]. 1988 [cited 2025 Jan 19];17(4):241\u20137. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.3109\/01050398809070712","DOI":"10.3109\/01050398809070712"},{"issue":"6","key":"4944_CR38","first-page":"641","volume":"73","author":"M Kashiwamura","year":"1998","unstructured":"Kashiwamura M (1998) [Studies of the evaluation of cochlea function with distortion product otoacoustic emission]. Hokkaido Igaku Zasshi 73(6):641\u2013662","journal-title":"Hokkaido Igaku Zasshi"},{"key":"4944_CR39","doi-asserted-by":"crossref","unstructured":"Ozturan O, Jerger J, Lew H, Lynch GR Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx [Internet]. 1996 [cited 2025 Jan 15];23(1):147\u201351. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8809338\/","DOI":"10.1016\/S0385-8146(96)80023-X"},{"key":"4944_CR40","doi-asserted-by":"crossref","unstructured":"Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G (2001) Evoked otoacoustic emissions - An approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol [Internet]. May 31 [cited 2022 Oct 23];59(1):47\u201357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11376818\/","DOI":"10.1016\/S0165-5876(01)00455-4"},{"key":"4944_CR41","doi-asserted-by":"crossref","unstructured":"Howarth A, Shone GR Ageing and the auditory system. Postgrad Med J [Internet]. 2006 Mar [cited 2022 Oct 23];82(965):166\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16517797\/","DOI":"10.1136\/pgmj.2005.039388"},{"key":"4944_CR42","doi-asserted-by":"publisher","unstructured":"Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong OS, Wallhagen MI The Contribution of Ototoxic Medications to Hearing Loss Among Older Adults. Journals Gerontol Ser A Biol Sci Med Sci [Internet]. 2020 Feb 14 [cited 2022 Nov 21];75(3):561. https:\/\/doi.org\/10.1093\/gerona\/glz166 https:\/\/doi.org\/10.1093\/gerona\/glz166","DOI":"10.1093\/gerona\/glz166"},{"key":"4944_CR43","doi-asserted-by":"crossref","unstructured":"Sanchez VA, Dinh PC, Rooker J, Monahan PO, Althouse SK, Fung C et al Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv [Internet]. 2023 Feb 1 [cited 2025 Feb 5];17(1):27\u201339. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36637632\/","DOI":"10.1007\/s11764-022-01313-w"},{"issue":"2","key":"4944_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000499599","volume":"14","author":"B Jordan","year":"2019","unstructured":"Jordan B, Jahn F, Sauer S, Jordan K (2019) Prevention and management of chemotherapy-induced polyneuropathy. Breast Care 14(2):79\u201384https:\/\/doi.org\/10.1159\/000499599 https:\/\/doi.org\/10.1159\/000499599","journal-title":"Breast Care"},{"issue":"2","key":"4944_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11764-017-0662-8","volume":"12","author":"C Miaskowski","year":"2018","unstructured":"Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors\u2019 symptom burden and quality of life. J Cancer Surviv 12(2):234\u2013245https:\/\/doi.org\/10.1007\/s11764-017-0662-8 https:\/\/doi.org\/10.1007\/s11764-017-0662-8","journal-title":"J Cancer Surviv"},{"key":"4944_CR46","doi-asserted-by":"publisher","unstructured":"Wei J, Hu Y, Zhang L, Hao Q, Yang R, Lu H et al (2017) Hearing Impairment, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Cohort Studies. Dement Geriatr Cogn Dis Extra [Internet]. Sep 28 [cited 2022 Nov 21];7(3):440. https:\/\/doi.org\/10.1159\/000485178 https:\/\/doi.org\/10.1159\/000485178","DOI":"10.1159\/000485178"},{"issue":"6","key":"4944_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000095275","volume":"68","author":"T Janssen","year":"2006","unstructured":"Janssen T, Niedermeyer HP, Arnold W (2006) Diagnostics of the cochlear amplifier by means of distortion product otoacoustic emissions. ORL 68(6):334\u2013339 https:\/\/doi.org\/10.1159\/000095275 https:\/\/doi.org\/10.1159\/000095275","journal-title":"ORL"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04944-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:30:18Z","timestamp":1788931818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04944-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4944"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04944-3","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors listed in the study declare no existing conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hospital Santa Casa de Porto Alegre and Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre in November 22, 2021, Ethics approval numbers: 5.117.189\/5.284.891 and was registered in Brazil\u2019s National System for Research Registration Involving Human Subjects (Plataforma Brasil \u2013 CAAE: 52572021.2.0000.5335).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"98"}}